These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 19399331)

  • 1. [Atypical antipsychotic induced weight gain and metabolic disorders].
    Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
    Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
    Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
    CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal glucose metabolism in patients treated with antipsychotics.
    Scheen AJ; De Hert MA
    Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies].
    Himmerich H; Schuld A; Pollmächer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S233-7. PubMed ID: 15586316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schizophrenia and comorbid metabolic disorders.
    Henderson DC
    J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design.
    Coccurello R; Moles A
    Pharmacol Ther; 2010 Sep; 127(3):210-51. PubMed ID: 20493213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
    Reynolds GP; Kirk SL
    Pharmacol Ther; 2010 Jan; 125(1):169-79. PubMed ID: 19931306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.